Monopar Therapeutics Inc(NASDAQ:MNPR) 
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the United States. It is involved in developing Validive, a clonidine mucobuccal tablet that is in Phase 2b/3 clinical trial for t...
Website: https://www.monopartx.com/
Founded: 2014
Full Time Employees: 6
CEO: Chandler Drew Robinson
Sector: Healthcare
Industry: Biotechnology
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 34.86
H 34.86
L 28.24
C 30.00
V 42,373
10EMA 30.00
20EMA 30.00
60EMA 30.00
120EMA 30.00
250EMA 30.00